



Testimony before the Human Services Committee

March 3, 2009

Opposed SB 843

Good evening, Senator Doyle, Representative Walker, and members of the Human Services Committee. My name is Kate Mattias, and I am the Executive Director of the National Alliance on Mental Illness, CT (NAMI-CT). I am here to testify with strong concern about several components of SB 843, An Act Implementing the Governor's Budget Recommendations Concerning Social Services.

NAMI-CT strongly opposes the Governor's recommendation to subject mental health related medications to the state's Preferred Drug List (PDL). This will greatly and disproportionately restrict access to psychiatric medications for low-income people with serious mental illnesses. Currently the state is required to make *all* mental health related drugs available. This policy is based on the common understanding that barriers to medication access for people with serious psychiatric disabilities most often lead to an interruption in their treatment and can have serious life-threatening consequences (please see attached). Psychiatric medications are often the only form of treatment that a person with a mental illness receives, and it can take years for an individual to find a medication that he or she responds to or a combination of medicines that work. Individualized clinical decision-making must be protected. Finding the right medication regimen is often dependent on the individual's relationship with the prescriber, and responses to medications vary tremendously.

The Governor also proposes to eliminate the Medicare Part D state wraparound that covers the co-pays for people who are dually eligible for Medicare and Medicaid and non-formulary drugs for those who are on Medicaid or ConnPACE. In 2006, the state made a promise to continue its obligation to these populations and to hold them harmless from changes in their drug coverage imposed by Part D. The state has and continues to save substantial amounts of money from the cost shifts to Part D, and the Governor is now trying to take away protections that preserved the stability of these vulnerable populations. For most people with Medicaid and ConnPACE, buying a medication outright is simply not an option, so they go without their vital prescriptions. Low income individuals on Medicaid and ConnPACE often face chronic diseases, mental illness, dementia, lack of phones and transportation, limited English proficiency, and the use of outpatient clinics with a rotating set of doctors, all of which dramatically increase the difficulty of working with their pharmacy and doctors to get their medications and navigating complicated utilization management processes. Again, this would disproportionately hit those with the least resources.

In a study of dual eligible Medicare Part D recipients with mental illness, over half had problems accessing needed medications. **The results: nearly one in five had an**

emergency room visit and over one in ten were hospitalized.¹ Among the most commonly reported problems were *not being able to access medication refills; discontinuing or temporarily stopping medications as a result of prescription drug plan management or coverage issues, or because patients could not afford copayments.*

Similarly, the Governor's proposals to restrict access to high cost drugs, reduce state supplement benefits, and eliminate Medicaid coverage for all dental services other than emergency – *are all extremely short sighted.* The loss of general dental services will lead to an increase in serious diseases and conditions related to poor oral health, such as systemic infections, heart disease, and diabetes, and it will further overwhelm emergency rooms and community clinics with dental emergencies. We are not going to resolve this budget crisis by taking from the most low-income and chronically ill people in our state. The costs of these decisions will spill out in other uncontrollable ways and as yet unforeseen damage will be the result.

Thank you for your time and attention. I would be happy to answer any questions.

¹ WEST, WILK, MUSZYNSKI, ET AL. Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients During the First 4 Months of the Medicare Prescription Drug Benefit, *Am J Psychiatry* 164:5, May 2007